Effects of dexmedetomidine on subthalamic local field potentials in Parkinson's disease.
Parkinson's disease
deep brain stimulation
dexmedetomidine
local field potentials
sedation
subthalamic activity
Journal
British journal of anaesthesia
ISSN: 1471-6771
Titre abrégé: Br J Anaesth
Pays: England
ID NLM: 0372541
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
29
07
2020
revised:
17
12
2020
accepted:
23
01
2021
pubmed:
27
4
2021
medline:
3
8
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
Dexmedetomidine is frequently used for sedation during deep brain stimulator implantation in patients with Parkinson's disease, but its effect on subthalamic nucleus activity is not well known. The aim of this study was to quantify the effect of increasing doses of dexmedetomidine in this population. Controlled clinical trial assessing changes in subthalamic activity with increasing doses of dexmedetomidine (from 0.2 to 0.6 μg kg With dexmedetomidine infusion, patients became clinically sedated, and at higher doses (0.5-0.6 μg kg Patients needing some degree of sedation throughout subthalamic deep brain stimulator implantation for Parkinson's disease can probably receive dexmedetomidine up to 0.6 μg kg EudraCT 2016-002680-34; NCT-02982512.
Sections du résumé
BACKGROUND
Dexmedetomidine is frequently used for sedation during deep brain stimulator implantation in patients with Parkinson's disease, but its effect on subthalamic nucleus activity is not well known. The aim of this study was to quantify the effect of increasing doses of dexmedetomidine in this population.
METHODS
Controlled clinical trial assessing changes in subthalamic activity with increasing doses of dexmedetomidine (from 0.2 to 0.6 μg kg
RESULTS
With dexmedetomidine infusion, patients became clinically sedated, and at higher doses (0.5-0.6 μg kg
CONCLUSIONS
Patients needing some degree of sedation throughout subthalamic deep brain stimulator implantation for Parkinson's disease can probably receive dexmedetomidine up to 0.6 μg kg
CLINICAL TRIAL REGISTRATION
EudraCT 2016-002680-34; NCT-02982512.
Identifiants
pubmed: 33896591
pii: S0007-0912(21)00171-9
doi: 10.1016/j.bja.2021.01.036
pmc: PMC8362272
pii:
doi:
Substances chimiques
Hypnotics and Sedatives
0
Dexmedetomidine
67VB76HONO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-253Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Mov Disord. 2006 Jun;21 Suppl 14:S259-83
pubmed: 16810720
Mov Disord. 2009 Jan 30;24(2):254-60
pubmed: 18951542
World Neurosurg. 2017 Sep;105:191-198
pubmed: 28526642
N Engl J Med. 2014 Oct 9;371(15):1369-73
pubmed: 25197963
Parkinsons Dis. 2019 Jan 17;2019:5676345
pubmed: 30800263
Eur J Neurosci. 2015 Aug;42(4):2070-7
pubmed: 26108432
Anesthesiology. 2015 Aug;123(2):357-67
pubmed: 26068206
Stereotact Funct Neurosurg. 2018;96(6):370-378
pubmed: 30517938
Neuromodulation. 2013 Sep-Oct;16(5):401-6; discussion 406
pubmed: 22780449
Mov Disord. 2016 Nov;31(11):1748-1751
pubmed: 27548068
Exp Neurol. 2013 Jul;245:77-86
pubmed: 23022916
J Neurosci Methods. 2010 Sep 30;192(1):146-51
pubmed: 20637804
N Engl J Med. 2013 Feb 14;368(7):610-22
pubmed: 23406026
Stereotact Funct Neurosurg. 2015;93(6):393-9
pubmed: 26671782
Stereotact Funct Neurosurg. 2017;95(1):40-48
pubmed: 28132061
Mov Disord. 2008 Jul 15;23(9):1317-20
pubmed: 18442130
Lancet Neurol. 2010 Jun;9(6):581-91
pubmed: 20434403
Front Neurosci. 2016 May 09;10:198
pubmed: 27242404
Curr Opin Anaesthesiol. 2015 Oct;28(5):505-10
pubmed: 26308514
Anesth Analg. 2006 Nov;103(5):1224-8
pubmed: 17056959
World Neurosurg. 2016 May;89:320-8
pubmed: 26805677
Exp Neurol. 2004 Oct;189(2):369-79
pubmed: 15380487
Neurology. 2017 Nov 7;89(19):1944-1950
pubmed: 28986415
Stereotact Funct Neurosurg. 2014;92(4):251-63
pubmed: 25170784
N Engl J Med. 2006 Aug 31;355(9):896-908
pubmed: 16943402
Ann Neurol. 1998 Oct;44(4):622-8
pubmed: 9778260
J Clin Neurosci. 2014 Oct;21(10):1790-5
pubmed: 24915957
World Neurosurg. 2018 Dec;120:e1217-e1224
pubmed: 30240865
J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):95-104
pubmed: 28866626
Anesthesiology. 2017 Jun;126(6):1033-1042
pubmed: 28492384
Curr Opin Anaesthesiol. 2011 Oct;24(5):495-9
pubmed: 21772140
J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1167-73
pubmed: 24249783
Mov Disord. 2018 Jul;33(6):900-908
pubmed: 29570862
Anesthesiology. 2014 Nov;121(5):978-89
pubmed: 25187999
J Neurosurg Anesthesiol. 2008 Jan;20(1):36-40
pubmed: 18157023
Anesth Analg. 2010 Apr 1;110(4):1138-45
pubmed: 20142347
Arch Neurol. 2004 Mar;61(3):390-2
pubmed: 15023817
Mov Disord. 2018 Oct;33(10):1540-1550
pubmed: 30288779
Expert Rev Neurother. 2015 Oct;15(10):1151-60
pubmed: 26377740